Material Insights · Understanding the Material World

CAR-T cell therapy: Overview

What it does

The job the technology does for people, in a short paragraph

CAR-T therapy treats some blood cancers by turning a patient's own immune cells into cancer killers [1]. The first was approved in the United States in 2017 for children with acute lymphoblastic leukaemia [1, 3]. By 2025 seven CAR-T therapies were approved there, for leukaemias, lymphomas and multiple myeloma [1].

as of 2026-11-11

How it works

The working principle in plain words, step by step

T cells are white blood cells that kill infected or abnormal cells, but they often miss cancer. Doctors first collect the patient's blood and separate out the T cells [1]. In a manufacturer's laboratory the cells receive a new gene so that they make a chimeric antigen receptor, or CAR, on their surface [1, 3]. The changed cells are grown to hundreds of millions and infused back in one dose [1]. When a CAR locks onto its marker on a cancer cell, such as CD19 on leukaemia cells, the T cell is switched on, kills the cell and multiplies [4].

as of 2026-11-11

Key figures

The handful of numbers that size it up, each with its unit, year and source

FigureValueUnitYearSource
CAR-T therapies approved by the US Food and Drug Administration7products2025[1]
Patients with complete remission after one dose in the trial behind Kymriah's approval83%2017[4]
Launch price of Kymriah, a one-time treatment475,000USD2017[5]
Time to make one patient's cells (low end of 3 to 5 weeks)3weeks2025[1]
Large cell lymphoma patients alive with no sign of cancer five years after treatment (more than)30%2025[1]

as of 2026-11-11. The NCI figures carry the page's update date of 26 February 2025; the remission and price figures carry the 2017 publication year of those reports, as neither sentence gives a data year [1, 4, 5].

Where it is used

The main places and products the technology is found in

  • B-cell acute lymphoblastic leukaemia in children and young adults
  • Large B-cell and other lymphomas
  • Multiple myeloma
  • Chronic lymphocytic leukaemia
  • Specialist cancer centres able to manage its side effects

as of 2026-11-11

Scale today

How much of it there is now: units in use, made each year and who uses it

Installed
Seven therapies approved in the United States [1]
Unit
approved products
Year
2025
Note
No count of patients treated worldwide was found; each dose is made for one patient [1].

as of 2026-11-11

Sources

  1. CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers National Cancer Institute (NIH), 2025
  2. FDA Approves Novartis' CAR-T Drug, First Gene Therapy Approval in US Pharmaceutical Technology, 2017
  3. FDA Approves Personalized Cellular Therapy for Advanced Leukemia (news release) Penn Medicine, 2017
  4. 'Historic Action': FDA Approves First CAR-T Therapy Regulatory Affairs Professionals Society (RAPS), 2017